CN115968293B - Cereblon结合化合物、其组合物及其用于治疗的方法 - Google Patents

Cereblon结合化合物、其组合物及其用于治疗的方法

Info

Publication number
CN115968293B
CN115968293B CN202180043585.3A CN202180043585A CN115968293B CN 115968293 B CN115968293 B CN 115968293B CN 202180043585 A CN202180043585 A CN 202180043585A CN 115968293 B CN115968293 B CN 115968293B
Authority
CN
China
Prior art keywords
methyl
trans
cyclohexyl
dimethyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180043585.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115968293A (zh
Inventor
M·D·亚历山大
M·D·科雷亚
D·达尔维
V·H·S·格兰特
J·汉森
R·L·哈里斯三世
E·J·霍恩
D·黄
C·梅恩
S·诺里斯
V·普列特文-克列尼茨基
J·J·萨皮恩扎
L·特赫拉尼
B·W·怀特菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinji
Original Assignee
Xinji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinji filed Critical Xinji
Publication of CN115968293A publication Critical patent/CN115968293A/zh
Application granted granted Critical
Publication of CN115968293B publication Critical patent/CN115968293B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180043585.3A 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法 Active CN115968293B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043650P 2020-06-24 2020-06-24
US63/043,650 2020-06-24
PCT/US2021/038629 WO2021262815A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
CN115968293A CN115968293A (zh) 2023-04-14
CN115968293B true CN115968293B (zh) 2025-08-26

Family

ID=79167578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043585.3A Active CN115968293B (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法

Country Status (9)

Country Link
US (1) US11560371B2 (https=)
EP (1) EP4171567B1 (https=)
JP (1) JP7781083B2 (https=)
KR (1) KR20230027214A (https=)
CN (1) CN115968293B (https=)
AR (1) AR122726A1 (https=)
ES (1) ES3047718T3 (https=)
TW (1) TW202216690A (https=)
WO (1) WO2021262815A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
CN110317192A (zh) 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Also Published As

Publication number Publication date
EP4171567B1 (en) 2025-09-03
CN115968293A (zh) 2023-04-14
JP2023531495A (ja) 2023-07-24
AR122726A1 (es) 2022-09-28
EP4171567A4 (en) 2024-07-24
ES3047718T3 (en) 2025-12-04
JP7781083B2 (ja) 2025-12-05
US11560371B2 (en) 2023-01-24
EP4171567A1 (en) 2023-05-03
TW202216690A (zh) 2022-05-01
US20220002273A1 (en) 2022-01-06
KR20230027214A (ko) 2023-02-27
WO2021262815A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CN115955979B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN115835866B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN115968293B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN113453681B (zh) 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
CN117561249A (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CN117545752A (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
EP4359404A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
EA047871B1 (ru) Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant